Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ablative Solutions Inc.

Targeted renal denervation

This article was originally published in Start Up

Executive Summary

Unlike other renal denervation technologies that apply destructive energy to the entire renal artery wall, , Ablative Solutions Inc. has developed a catheter-based approach that delivers ethanol directly to the nerves that encircle the renal artery, and destroys them without damaging the artery walls . The company is developing its Peregrine System for use in an outpatient setting to restore normal blood pressure in medication-resistant hypertensive patients.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts